Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 164

1.

Mechanisms of resistance to HER family targeting antibodies.

Kruser TJ, Wheeler DL.

Exp Cell Res. 2010 Apr 15;316(7):1083-100. doi: 10.1016/j.yexcr.2010.01.009. Epub 2010 Jan 11. Review.

PMID:
20064507
2.

The ErbB/HER receptor protein-tyrosine kinases and cancer.

Roskoski R Jr.

Biochem Biophys Res Commun. 2004 Jun 18;319(1):1-11. Review.

PMID:
15158434
3.

Therapeutic targeting of the epidermal growth factor receptor in human cancer.

Dhomen NS, Mariadason J, Tebbutt N, Scott AM.

Crit Rev Oncog. 2012;17(1):31-50. Review.

PMID:
22471663
4.

EGFR signaling and drug discovery.

Lurje G, Lenz HJ.

Oncology. 2009;77(6):400-10. doi: 10.1159/000279388. Epub 2010 Feb 2. Review.

PMID:
20130423
5.

Progression and treatment of HER2-positive breast cancer.

Davoli A, Hocevar BA, Brown TL.

Cancer Chemother Pharmacol. 2010 Mar;65(4):611-23. doi: 10.1007/s00280-009-1208-1. Epub 2009 Dec 20.

PMID:
20087739
6.

The ErbB/HER family of protein-tyrosine kinases and cancer.

Roskoski R Jr.

Pharmacol Res. 2014 Jan;79:34-74. doi: 10.1016/j.phrs.2013.11.002. Epub 2013 Nov 20. Review.

PMID:
24269963
7.

Growth stimulation of non-small cell lung cancer cell lines by antibody against epidermal growth factor receptor promoting formation of ErbB2/ErbB3 heterodimers.

Maegawa M, Takeuchi K, Funakoshi E, Kawasaki K, Nishio K, Shimizu N, Ito F.

Mol Cancer Res. 2007 Apr;5(4):393-401.

8.

HER2-targeted therapy in breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors.

Nielsen DL, Andersson M, Kamby C.

Cancer Treat Rev. 2009 Apr;35(2):121-36. doi: 10.1016/j.ctrv.2008.09.003. Epub 2008 Nov 12. Review.

PMID:
19008049
9.

Critical update and emerging trends in epidermal growth factor receptor targeting in cancer.

Baselga J, Arteaga CL.

J Clin Oncol. 2005 Apr 10;23(11):2445-59. Epub 2005 Mar 7. Review. Erratum in: J Clin Oncol. 2005 Sep 1;23(25):6281.

PMID:
15753456
10.

Acquired resistance to small molecule ErbB2 tyrosine kinase inhibitors.

Chen FL, Xia W, Spector NL.

Clin Cancer Res. 2008 Nov 1;14(21):6730-4. doi: 10.1158/1078-0432.CCR-08-0581. Review.

11.

EGFR targeting therapies: monoclonal antibodies versus tyrosine kinase inhibitors. Similarities and differences.

Dassonville O, Bozec A, Fischel JL, Milano G.

Crit Rev Oncol Hematol. 2007 Apr;62(1):53-61. Epub 2007 Feb 26. Review.

PMID:
17324578
12.

Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu).

Reid A, Vidal L, Shaw H, de Bono J.

Eur J Cancer. 2007 Feb;43(3):481-9. Epub 2007 Jan 8. Review.

PMID:
17208435
13.

The role of EGFR inhibitors in nonsmall cell lung cancer.

Ciardiello F, De Vita F, Orditura M, Tortora G.

Curr Opin Oncol. 2004 Mar;16(2):130-5. Review.

PMID:
15075904
14.

Rational combination of targeted therapies as a strategy to overcome the mechanisms of resistance to inhibitors of EGFR signaling.

Bianco R, Damiano V, Gelardi T, Daniele G, Ciardiello F, Tortora G.

Curr Pharm Des. 2007;13(33):3358-67. Review.

PMID:
18045190
15.

Targeting ErbB receptors in high-grade glioma.

Berezowska S, Schlegel J.

Curr Pharm Des. 2011;17(23):2468-87. Review.

PMID:
21827413
16.

New strategies to overcome limitations of reversible EGFR tyrosine kinase inhibitor therapy in non-small cell lung cancer.

Doebele RC, Oton AB, Peled N, Camidge DR, Bunn PA Jr.

Lung Cancer. 2010 Jul;69(1):1-12. doi: 10.1016/j.lungcan.2009.12.009. Epub 2010 Jan 25. Review.

PMID:
20092908
17.

Epidermal growth factor receptor inhibitors: a new prospective in the treatment of lung cancer.

Tiseo M, Loprevite M, Ardizzoni A.

Curr Med Chem Anticancer Agents. 2004 Mar;4(2):139-48. Review.

PMID:
15032719
18.

Epidermal growth factor receptor inhibitors in cancer treatment: advances, challenges and opportunities.

Modjtahedi H, Essapen S.

Anticancer Drugs. 2009 Nov;20(10):851-5. doi: 10.1097/CAD.0b013e3283330590. Review.

PMID:
19826350
19.

AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.

Traxler P, Allegrini PR, Brandt R, Brueggen J, Cozens R, Fabbro D, Grosios K, Lane HA, McSheehy P, Mestan J, Meyer T, Tang C, Wartmann M, Wood J, Caravatti G.

Cancer Res. 2004 Jul 15;64(14):4931-41.

20.

New drugs in cancer therapy, National Tumor Institute, Naples, 17-18 June 2004.

Caponigro F, Basile M, de Rosa V, Normanno N.

Anticancer Drugs. 2005 Feb;16(2):211-21.

PMID:
15655420

Supplemental Content

Support Center